Jane Street
RNAZ icon

Jane Street’s TransCode Therapeutics RNAZ Stock Holding History

Jane Street’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43
Closed -$22.7K – 10387
2024
Q3 		$22.7K Buy
+43
New +$17.4K ﹤0.01% 9283

Other funds holding RNAZ

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Jane Street's RNAZ Position: Q4 2024 in Review

Jane Street sold out of TransCode Therapeutics (RNAZ) in Q4 2024, closing a stake of 43 shares — an estimated $22.7K sold.

Jane Street first reported a position in RNAZ in Q3 2024 and held it in 1 quarter. The position peaked at $22.7K in Q3 2024. 3 funds tracked by Wall St. Rank hold RNAZ as of Q4 2024.

  • Jane Street reported no remaining TransCode Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jane Street sold 43 TransCode Therapeutics shares in Q4 2024, an estimated $22.7K.
  • Jane Street first reported a position in TransCode Therapeutics in Q3 2024 and held it in 1 quarter.
  • Jane Street's TransCode Therapeutics position peaked at $22.7K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2024.

Based on Jane Street's 13F filing for Q4 2024, filed 14 Feb 2025.